The EGFP mRNA will express an enhanced version of the green fluorescent protein, originally isolated from the jellyfish, Aequorea victoria. EGFP is a commonly used direct detection reporter in mammalian cell culture, yielding bright green fluorescence with an emission peak at 509 nm.
This mRNA is capped using CleanCap, TriLink's proprietary co-transciptional capping method, which results in the naturally occuring Cap 1 structure with high capping efficiency. It is polyadenylated, modified with 5-methoxyuridine and optimized for mammalian systems. It mimics a fully processed mature mRNA.
|Purity||Passes Agarose Gel Mobility|
|Base Composition||Fully substituted with 5-Methoxy-U|
|Buffer||1 mM Sodium Citrate pH 6.4|
|Conversion Factor||40 µg/OD260|
|Recommended Storage||At or below -40°C|
|Cap||AG Start, Cap 1, CleanCap|
|Other Name(s)||CleanCap®Enhanced Green Fluorescent Protein mRNA (5-methoxyuridine)|
CleanCap For Research Use Only. Not for use in humans. Not for use in diagnostic or therapeutic purposes. For additional licensing restrictions, please see the license agreement at trilinkbiotech.com/cleancap-research-license. Patent or patent pending,see trilinkbiotech.com/legal-notices.
Mutant GFP mRNA These products are sold with a Limited Use Label License under sublicense with Life Technologies, Inc. Please review Limited License at trilinkbiotech.com/gfp-label-license.
Products are for research use only, not for use in diagnostic or therapeutic procedures or for use in humans. Products are not for resale without express written permission of Seller. No license under any patent or other intellectual property right of Seller or its licensors is granted or implied by the purchase unless otherwise provided in writing.
TriLink does not warrant that the use or sale of the products delivered hereunder will not infringe the claims of any United States or other patents or patents pending covering the use of the product alone or in combination with other products or in the operation of any process. All and any use of TriLink product is the purchaser's sole responsibility.
Fornaguera, Cristina; Guerra-Rebollo, Marta; Ángel Lázaro, Miguel; Castells-Sala, Cristina; Meca-Cortés, Oscar; Ramos-Pérez, Victor; Cascante, Anna; Rubio, Núria; Blanco, Jerónimo; Borrós, Salvador . mRNA Delivery System for Targeting Antigen-Presenting Cells In Vivo.
Kauffman, Amy C.; Piotrowski-Daspit, Alexandra S.; Nakazawa, Kay H.; Jiang, Yuhang; Datye, Amit; Saltzman, W. Mark . Tunability of Biodegradable Poly(amine- co-ester) Polymers for Customized Nucleic Acid Delivery and Other Biomedical Applications.
Estrada, K;Froelich, S;Wuster, A;Bauer, CR;Sterling, T;Clark, WT;Ru, Y;Trinidad, M;Nguyen, HP;Luu, AR;Wendt, DJ;Yogalingam, G;Yu, GK;LeBowitz, JH;Cardon, LR; . Identifying therapeutic drug targets using bidirectional effect genes
Gómez-Aguado, I;Rodríguez-Castejón, J;Beraza-Millor, M;Vicente-Pascual, M;Rodríguez-Gascón, A;Garelli, S;Battaglia, L;Del Pozo-Rodríguez, A;Solinís, MÁ; . mRNA-Based Nanomedicinal Products to Address Corneal Inflammation by Interleukin-10 Supplementation
Tam, A;Leclair, P;Li, LV;Yang, CX;Li, X;Witzigmann, D;Kulkarni, JA;Hackett, TL;Dorscheid, DR;Singhera, GK;Hogg, JC;Cullis, PR;Sin, DD;Lim, CJ; . FAM13A as potential therapeutic target in modulating TGF-beta-induced airway tissue remodeling in COPD
Legere, RM;Cohen, ND;Poveda, C;Bray, JM;Barhoumi, R;Szule, JA;de la Concha-Bermejillo, A;Bordin, AI;Pollet, J; . Safe and effective aerosolization of in vitro transcribed mRNA to the respiratory tract epithelium of horses without a transfection agent
Zhang, H;Bussmann, J;Huhnke, FH;Devoldere, J;Minnaert, AK;Jiskoot, W;Serwane, F;Spatz, J;R . Together is Better: mRNA Co-Encapsulation in Lipoplexes is Required to Obtain Ratiometric Co-Delivery and Protein Expression on the Single Cell Level
Rui, Y;Wilson, DR;Tzeng, SY;Yamagata, HM;Sudhakar, D;Conge, M;Berlinicke, CA;Zack, DJ;Tuesca, A;Green, JJ; . High-throughput and high-content bioassay enables tuning of polyester nanoparticles for cellular uptake, endosomal escape, and systemic in vivo delivery of mRNA
Shi, Y;Lu, Y;Qin, B;Jiang, M;Guo, X;Li, X;Liu, Y;Huang, J;Zhang, J;Luo, Z;Yin, H;Liu, H;Guan, G;Du, Y;Peng, L;You, J; . Antigen transfer from non-APCs to APCs impacts the efficacy and safety of protein- and mRNA- based vaccines